PMID- 20567822
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 59
IP  - 10
DP  - 2010 Oct
TI  - CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant 
      pleural mesothelioma after resection.
PG  - 1543-9
LID - 10.1007/s00262-010-0881-6 [doi]
AB  - Defects in human leukocyte antigen (HLA) class I expression may allow tumor cells 
      to escape immune recognition. T cell infiltration is associated with a good 
      prognosis in many cancers. However, the role of HLA class I expression and 
      tumor-infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM) has 
      not been fully analyzed. In the present study, we investigated the immune 
      profiles and conducted outcome analyses of MPM patients. HLA class I expression 
      and TILs (CD4(+), CD8(+), and NK cells) were detected by immunohistochemistry in 
      a series of 44 MPM cases. To detect HLA class I expression, specimens were 
      stained with the anti-pan HLA class I monoclonal antibody EMR8-5. The expression 
      of HLA class I was positive in all patients. There was no case that showed 
      negative HLA class I expression. The density of CD4(+) and CD8(+) TILs were 
      strongly correlated (R = 0.76, p < 0.001). A high density of CD8(+) TILs was a 
      significantly better prognostic factor for the survival of patients with 
      extrapleural pneumonectomy (p < 0.05). Multivariate analysis revealed that a high 
      density of CD8(+) TILs is an independent prognostic factor for patients who 
      underwent extrapleural pneumonectomy. The presence of intratumoral CD8(+) T cells 
      was correlated with an improved clinical outcome, raising the possibility that 
      CD8(+) T cells might play a pivotal role in the antitumor immune response against 
      MPMs. Thus, the stimulation of CD8(+) lymphocytes might be an efficacious 
      immunotherapy for MPM patients.
FAU - Yamada, Noriyuki
AU  - Yamada N
AD  - First Department of Medicine, Hokkaido University School of Medicine, North 15, 
      West 7, Kita-ku, Sapporo, 060-8638, Japan.
FAU - Oizumi, Satoshi
AU  - Oizumi S
FAU - Kikuchi, Eiki
AU  - Kikuchi E
FAU - Shinagawa, Naofumi
AU  - Shinagawa N
FAU - Konishi-Sakakibara, Jun
AU  - Konishi-Sakakibara J
FAU - Ishimine, Atsushi
AU  - Ishimine A
FAU - Aoe, Keisuke
AU  - Aoe K
FAU - Gemba, Kenichi
AU  - Gemba K
FAU - Kishimoto, Takumi
AU  - Kishimoto T
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Nishimura, Masaharu
AU  - Nishimura M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100622
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Mesothelioma/*immunology/*physiopathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pleural Neoplasms/*immunology/*physiopathology
MH  - Prognosis
PMC - PMC11030611
EDAT- 2010/06/23 06:00
MHDA- 2010/08/17 06:00
PMCR- 2010/06/22
CRDT- 2010/06/23 06:00
PHST- 2010/03/21 00:00 [received]
PHST- 2010/06/07 00:00 [accepted]
PHST- 2010/06/23 06:00 [entrez]
PHST- 2010/06/23 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
PHST- 2010/06/22 00:00 [pmc-release]
AID - 881 [pii]
AID - 10.1007/s00262-010-0881-6 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2010 Oct;59(10):1543-9. doi: 
      10.1007/s00262-010-0881-6. Epub 2010 Jun 22.